Combo Extends OS in Patients 65+ with Ph+ ALL

Long-term results show combination treatment that skips chemotherapy is effective for older patients with Ph+ ALL

Model Predicts AI Non-adherence Risk

A new risk model uses baseline sociodemographic and financial measures to predict which patients prescribed long-term therapy with aromatase inhibitors for breast cancer are at significantly higher risk of stopping that therapy early

Lung-MAP Shows Potential of Public-Private Partnerships

Ten years on, Lung-MAP success demonstrates potential of public-private partnerships in clinical research

ECOG-ACRIN and PrECOG announce multiple presentations at ASH 2023

Researchers with the ECOG-ACRIN Cancer Research Group and PrECOG, LLC will present six oral and three poster presentations at the 65th American Society of Hematology Meeting & Exposition

Bladder Cancer Subtype Association with Response

RNA-based molecular subtypes modestly improved predictions for pathologic downstaging in muscle-invasive bladder cancer.

FORTE, a Colorectal Cancer Prevention Clinical Trial, accrues its first 1,000 participants

The FORTE colorectal cancer prevention trial led by NRG Oncology, examining surveillance colonoscopy intervals in participants who have non-advanced polyps, recently accrued its 1000th participant

New Vice Chair named for NRG Health Disparities Committee

Dr. Evan M. Graboyes was recently named Vice Chair of the NRG Health Disparities Committee

Pembro before Surgery Shrinks Advanced Melanomas

In exploratory analyses of results from the S1801 trial in patients with stage III-IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant pembrolizumab

Alliance Presents Detailed Results from Phase III CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors at ESMO 2023

The CABINET trial demonstrated that cabozantinib provided dramatic improvements in median progression-free survival for patients with advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic neuroendocrine tumors

Adjuvant Benefit in Highest Risk Clear-Cell RCC

A secondary analysis from the EVEREST trial has found that in the subgroup of patients with clear-cell renal cell carcinoma who were at very-high risk of recurrence, those who were treated with everolimus after surgery had a statistically significant improvement in recurrence-free survival compared to patients getting placebo after surgery